La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Chilean Cobalt a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Chilean Cobalt..

Chilean Cobalt (OTC:COBA) Azioni, Catena delle Opzioni

Chilean Cobalt Corp is a primary cobalt, secondary copper, junior mining and exploration company. It is a critical materials exploration and development company focused on developing the La Cobaltera project located in Chile's historic San Juan cobalt district. La Cobaltera is a district-scale opportunity across C3's 2,635 hectares of 100 percent owned and unencumbered mining property situated in the San Juan District in northern Chile (Atacama Region III), a historic mining district with numerous past-producing mines and excellent infrastructure and accessibility.

CHILEAN COBALT CORP by CHILEAN COBALT CORP.

Chilean Cobalt Corp

CoBank ACB Non-Cum Perp Pfd Shs Series -H-

Cobak Token

Cobalt Blue Holdings Ltd

Baird analyst David Tarantino maintains Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) with a Outperform and lowers the price target from $68 to $62.

News

Price Target

Analyst Ratings

Baird Maintains Outperform on Chipotle Mexican Grill, Lowers Price Target to $62

<a href="https://www.jnj.com/media-center/press-releases/european-commission-approves-johnson-johnsons-subcutaneous-darzalex-daratumumab-based-quadruplet-regimen-for-the-treatment-of-patients-with-newly-diagnosed-multiple-myeloma-regardless-of-transplant-eligibility" title="https://www.jnj.com/media-center/press-releases/european-commission-approves-johnson-johnsons-subcutaneous-darzalex-daratumumab-based-quadruplet-regimen-for-the-treatment-of-patients-with-newly-diagnosed-multiple-myeloma-regardless-of-transplant-eligibility">https://www.jnj.com/media-center/press-releases/european-commission-approves-johnson-johnsons-subcutaneous-darzalex-daratumumab-based-quadruplet-regimen-for-the-treatment-of-patients-with-newly-diagnosed-multiple-myeloma-regardless-of-transplant-eligibility</a>

Biotech

General

Johnson & Johnson Announces The European Commission Has Approved Its Subcutaneous Darzalex-Based Quadruplet Regimen For The Treatment Of Patients With Newly Diagnosed Multiple Myeloma, Regardless Of Transplant Eligibility

Baird analyst David Tarantino maintains Cava Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) with a Outperform and lowers the price target from $125 to $105.

CAVA

Baird Maintains Outperform on Cava Group, Lowers Price Target to $105

Baird analyst David Tarantino maintains Cheesecake Factory (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAKE#NASDAQ">CAKE</a>) with a Neutral and lowers the price target from $50 to $46.

CAKE

Baird Maintains Neutral on Cheesecake Factory, Lowers Price Target to $46

Baird analyst David Tarantino maintains Dutch Bros (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) with a Outperform and lowers the price target from $80 to $66.

BROS

Baird Maintains Outperform on Dutch Bros, Lowers Price Target to $66

Gilat Satellite Networks Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILT#NASDAQ">GILT</a>) announced on Monday that it has <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44663247/gilat-awarded-up-to-23-million-multi-year-contract-to-service-satellite-transportable-terminal-uni" rel="noreferrer noopener">secured a contract</a> to deliver ongoing sustainment and support services for Satellite Transportable Terminal (STT) units deployed globally in support of U.S. Department of Defense (DoD) operations.
The agreement includes a base term with optional extensions of up to five years, bringing the total potential contract value to $23 million.
Under the terms of the deal, Gilat Defense will provide critical program management, field services, and technical support to ensure the operational readiness and long-term reliability of these vital communication systems.
"This contract reinforces the ongoing critical role our SATCOM systems play in supporting the U.S. DoD's global operations. We remain committed to delivering superior performance and service to our trusted defense partners worldwide," said Nicole Robinson, President of Gilat DataPath.
The announcement follows a $6 million <a href="https://www.benzinga.com/pressreleases/25/03/g44137836/gilat-receives-6-million-defense-contract-to-provide-military-communications-solutions-in-asia-pac" target="_blank" rel="noreferrer noopener">order</a> last month, in which Gilat's Defense Division was selected to supply an Asian-Pacific military organization with its advanced SkyEdge II-c platform. The system will support secure communications across fixed and mobile defense sites and feature enhanced air interface cybersecurity.
Price Action: At the last check on Monday, Gilat shares were trading higher by 4.35% at $5.76 premarket.

Contracts

GILT

Gilat Wins Defense Support Deal Worth Up To $23 Million For Global SATCOM Services

Baird analyst David George upgrades KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>) from Neutral to Outperform and maintains the price target from $18 to $18.

Upgrades

Baird Upgrades KeyCorp to Outperform, Maintains Price Target to $18

UBS analyst Joshua Spector upgrades Sealed Air (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEE#NYSE">SEE</a>) from Neutral to Buy and maintains the price target from $38 to $38.

UBS Upgrades Sealed Air to Buy, Maintains Price Target to $38

Earnings

HTLM

Homestolife FY 2024 GAAP EPS $(0.11) Down From $0.02 YoY, Sales $4.173M Down From $5.072M YoY

Collaboration Seeks to Enhance Ukraine's Mine Action Capabilities with Safe Pro's Cutting-Edge Patented AI Technology
Safe Pro Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPAI#NASDAQ">SPAI</a>) ("Safe Pro" or the "Company"), a leader in artificial intelligence (AI)-powered defense and security solutions, has entered into a multi-year Memorandum of Understanding (MOU) with Ukraine's Center of Excellence for Mine Action and Environmental Security (the "Center of Excellence" or "the Center"). Together, they will exam ways to integrate Safe Pro's patented AI-powered image processing technology, SpotlightAI&#x2122;, into Ukraine's demining methodologies and training programs to modernize the nation's approach to landmine detection and clearance.

SPAI

Safe Pro Group Enters Multi-Year MOU With Ukraine's Center Of Excellence For Mine Action To Integrate SpotlightAI Into Ukraine's Demining Methodologies And Training Programs To Enhance Landmine Detection And Clearance

Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) will release earnings results for the second quarter, before the <a href="https://www.benzinga.com/quote/WBA/earnings">opening bell on Tuesday, April 8.</a>
Analysts expect the company to report quarterly earnings at 53 cents per share, down from $1.2 per share in the year-ago period. According to data from Benzinga Pro, Walgreens projects quarterly revenue at $38.0 billion, compared to $37.05 billion a year earlier.
On March 6, Walgreens Boots Alliance entered an agreement to be acquired by private equity firm Sycamore Partners.
With the recent buzz around Walgreens, some investors may also be eyeing potential gains from the company's dividends. As of now, Walgreens offers an annual dividend yield of 9.36%, which is a quarterly dividend amount of 25 cents per share ($1.00 a year).  
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $64,080 or around 6,000 shares. For a more modest $100 per month or $1,200 per year, you would need $12,816 or around 1,200 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($1.00 in this case). So, $6,000 / $1.00 = 6,000 ($500 per month), and $1,200 / $1.00 = 1,200 shares ($100 per month).
Note that dividend yield can change on a rolling basis as the dividend payment and stock price fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
WBA Price Action: Shares of Walgreens fell 3.4% to close at $10.68 on Friday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44645517/wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-with-over-4-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Markets

Trading Ideas

How To Earn $500 A Month From Walgreens Stock Ahead Of Q2 Earnings

UBS analyst Joshua Spector downgrades LyondellBasell Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>) from Neutral to Sell and lowers the price target from $76 to $51.

Downgrades

UBS Downgrades LyondellBasell Industries to Sell, Lowers Price Target to $51

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/04/04/final-trades-jpmorgan-amazon-rh-and-the-2-year-treasury.html">Halftime Report Final Trades</a>,&#8221; Jason Snipe of Odyssey Capital Advisors said Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) is 30% off the 52-week high level.
Adding support to his choice, WestPark Capital analyst Curtis Shauger, on April 1, initiated coverage on Amazon.com with a Buy rating and announced a price target of $280.
Stephen L. Weiss of Short Hills Capital Partners named U.S. 2 Year Treasury as <a href="https://www.benzinga.com/topic/treasury-yields">his final trade</a>.
Jim Lebenthal of Cerity Partners picked JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) ahead of first-quarter earnings.
JPMorgan will host a conference call to review first-quarter financial results on Friday, April 11. Analysts expect the bank to report quarterly earnings at $4.65 per share, up from $4.44 per share in the year-ago period. JPMorgan projects quarterly revenue of $44.05 billion, compared to $41.93 billion a year earlier.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Bryn Talkington of Requisite Capital Management said RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) is another name she likes in her Vietnam basket.
On the earnings front, RH, on April 2, reported fourth-quarter revenue of $812.41 million, missing the consensus estimate of $829.56 million, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. The luxury retailer reported fourth-quarter adjusted earnings of $1.58 per share, missing analyst estimates of $1.92 per share.
Price Action:
<ul>
<li>JPMorgan shares dipped 7.5% to close at $210.28 on Friday.</li>
<li>Amazon shares fell 4.2% to close at $171.00 during Friday's session.</li>
<li>RH shares declined 2.5% to settle at $145.66 on Friday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44645517/wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-with-over-4-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields</a></li>
</ul>
Image: Shutterstock

Media

AMZN

Amazon, JPMorgan, RH And More: CNBC's 'Final Trades'

Baird analyst David George upgrades First Horizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHN#NYSE">FHN</a>) from Neutral to Outperform and maintains the price target from $22 to $22.

Baird Upgrades First Horizon to Outperform, Maintains Price Target to $22

UBS analyst Joshua Spector upgrades Axalta Coating Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXTA#NYSE">AXTA</a>) from Neutral to Buy and lowers the price target from $42 to $40.

AXTA

UBS Upgrades Axalta Coating Systems to Buy, Lowers Price Target to $40

Baird analyst David George upgrades Fifth Third Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FITB#NASDAQ">FITB</a>) from Neutral to Outperform and maintains the price target from $47 to $47.

FITB

Baird Upgrades Fifth Third Bancorp to Outperform, Maintains Price Target to $47

NMAX

Newsmax Enters Standby Equity Purchase Agreement For Up To $1.2B With Yorkville Advisors

The Company's flagship patented nicotinamide riboside (NR) ingredient, Niagen&#xAE;, is manufactured, encapsulated, and bottled in the U.S. and is currently classified as exempt from tariffs, minimizing exposure to tariff-related risks

NAGE

Niagen Bioscience Confirms Its Operations Of Niagen Currently Classified As Exempt From Tariffs

<ul>
<li>Conduit expands its partnership with Sarborg to apply advanced machine learning-driven analysis on clinical data from its AstraZeneca-acquired assets, aiming to uncover new insights and optimize development pathways. &nbsp;</li>
</ul>
NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 07, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today announces that it has entered into an additional license and use agreement (the "Additional Agreement") with&nbsp;Sarborg Limited&nbsp;("Sarborg") to expand the scope of work on Conduit's acquired AstraZeneca assets, including&nbsp;AZD1656, AZD5658, and AZD5904.
Under the agreement,&nbsp;Sarborg&nbsp;will apply its proprietary&nbsp;machine learning algorithms&nbsp;to conduct an in-depth analysis of Conduit's clinical and safety data, with the goal of uncovering missed insights, identifying potential drug repurposing opportunities, and highlighting gaps in existing datasets. A key focus will be the re-evaluation of historical clinical trial data, including endpoints, to determine whether specific patient subgroups may have demonstrated therapeutic benefits, findings that could refine Conduit's future clinical development strategy.
Sarborg has granted Conduit a&nbsp;non-exclusive, non-transferable license&nbsp;to access its advanced algorithmic platform for the duration of the six-month agreement. The collaboration builds upon the existing&nbsp;Services Agreement&nbsp;between the two parties, which remains in full effect.

Conduit Pharmaceuticals Expands Partnership With Sarborg To Apply Advanced Machine Learning Analysis On Clinical Data From AstraZeneca-Acquired Assets, Aiming To Uncover New Insights And Optimize Development Pathways For AZD1656, AZD5658, And AZD5904

Baird analyst David Tarantino downgrades Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) from Outperform to Neutral and lowers the price target from $114 to $85.

Comments

Chilean Cobalt

Chilean Cobalt (COBA) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO